FTC and New York settle with Vyera ahead of trial
Vyera Pharmaceuticals has agreed to pay up to $40 million to settle allegations that it illegally prevented generic competition for its infection treatment Daraprim.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10